CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Podcast

Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab into clinical practice.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Regeneron Pharmaceuticals, we passed the mic to Nikhil I. Khushalani, MD, who moderated an OncLive® Peer Exchange on updates in the treatment of patients with resectable cutaneous squamous cell carcinoma (CSCC). Dr Khushalani was joined by Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; and Vishal A. Patel, MD, FAAD, FACMS.

Dr Khushalani is vice chair of the Department of Cutaneous Oncology at Moffitt Cancer Center in Tampa, Florida. Dr Dietrich is a medical oncologist at Florida Cancer Specialists & Research Institute and an assistant professor of internal medicine at the University of Central Florida in Orlando. Dr Luke is director of the Cancer Immunotherapeutics Center in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine in Pennsylvania. Dr Patel is an assistant professor of dermatology at the GW School of Medicine & Health Sciences and the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC.

In this exclusive conversation, Drs Khushalani, Dietrich, Luke, and Patel discussed the nuances of defining resectability in CSCC, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab-rwlc (Libtayo) into clinical practice.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Regeneron Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Experts on myelodysplastic syndrome
Experts on myelodysplastic syndrome
Andrew Kuykendall, MD
Expert on FL
Experts on FL
Inderjit Mehmi, MD
Experts on ALL
Experts on ALL
Expert on follicular lymphoma
Avan Armaghani, breast medical oncologist, Moffitt Cancer Center
Related Content